Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara (updated)

Alvotech SA

21/02/2025 11:27

(Adds background throughout)
       Feb 21 (Reuters) - Teva Pharmaceuticals  TEVA.TA  and
Alvotech  ALVO.O  said on Friday they have launched a biosimilar
to Johnson & Johnson's  JNJ.N  autoimmune drug Stelara in the
United States.
    Selarsdi, like Stelara, is approved for the treatment of
moderate to severe plaque psoriasis, active psoriatic arthritis,
and moderately to severely active Crohn's disease and ulcerative
colitis.
        Stelara, introduced in 2009, has been J&J's top-selling
drug since 2019. Amgen  AMGN.O  in 2023 reached a settlement to
delay the launch of its biosimilar, with the treatment only
launching in January this year.

 (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh
Kuber)
 ((Kamal.Choudhury@thomsonreuters.com;))